Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a significant increase in short interest in February. As of February 27th, there was short interest totaling 2,971,195 shares, an increase of 20.5% from the February 12th total of 2,466,525 shares. Based on an average daily trading volume, of 516,202 shares, the short-interest ratio is currently 5.8 days. Approximately 16.4% of the company’s shares are sold short. Approximately 16.4% of the company’s shares are sold short. Based on an average daily trading volume, of 516,202 shares, the short-interest ratio is currently 5.8 days.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at about $74,000. Baird Financial Group Inc. purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $45,000. State Street Corp increased its position in shares of Karyopharm Therapeutics by 27.2% during the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after acquiring an additional 12,600 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $95,000. Finally, XTX Topco Ltd purchased a new position in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a research note on Wednesday, December 17th. Piper Sandler restated an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Finally, Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.71.

Karyopharm Therapeutics Price Performance

KPTI stock traded down $0.17 on Tuesday, reaching $8.38. 702,459 shares of the company traded hands, compared to its average volume of 609,852. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.99. The company has a market cap of $153.72 million, a P/E ratio of -0.50 and a beta of 0.13. The firm has a fifty day simple moving average of $7.88 and a 200-day simple moving average of $6.83.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Friday, February 13th. The company reported ($2.23) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.03. The company had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million. On average, sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.